<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Use of thiazide diuretics in patients with primary (essential) hypertension
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Use of thiazide diuretics in patients with primary (essential) hypertension
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Use of thiazide diuretics in patients with primary (essential) hypertension
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Johannes FE Mann, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karl F Hilgers, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George L Bakris, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 07, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thiazide and thiazide-like diuretics have been a mainstay of the therapy of primary hypertension. The most popular agent in this class,
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         , was traditionally used in doses of 50 to 100 mg/day. These doses were associated with metabolic and electrolyte complications. Low-dose therapy has since been demonstrated to be efficacious and to have a much lower incidence of side effects.
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          Chlorthalidone
         </a>
         and
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         , both thiazide-like diuretics, have been shown to provide greater antihypertensive efficacy and, more importantly, to reduce cardiovascular events and mortality compared with hydrochlorothiazide (a thiazide-type diuretic) [
         <a href="#rid1">
          1
         </a>
         ]. No trial has documented a mortality benefit from hydrochlorothiazide.
        </p>
        <p>
         This topic will review the antihypertensive mechanisms of thiazide and thiazide-like therapy, the common side effects associated with high doses of these diuretics, and the benefits of low-dose therapy. The role of these drugs in the treatment of primary hypertension is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ANTIHYPERTENSIVE MECHANISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanisms responsible for the decline in blood pressure (BP) are incompletely understood. The BP response appears to require initial volume loss (averaging approximately 1.5 kg) since it is not seen in patients who are resistant to the diuretic or who are ingesting a high-salt diet [
         <a href="#rid2">
          2
         </a>
         ]. The BP in responders begins to fall within the first week, but a slow decline can continue for as long as 12 weeks [
         <a href="#rid3">
          3
         </a>
         ]. Longer-acting diuretics are more effective than short-acting loop diuretics in patients with mild to moderate primary hypertension because they maintain the decline in intravascular volume. (See
         <a class="medical medical_review" href="/z/d/html/3871.html" rel="external">
          "Thiazides versus loop diuretics in the treatment of hypertension"
         </a>
         .)
        </p>
        <p>
         The initial hypotensive response is mediated by a modest reduction in plasma volume and cardiac output [
         <a href="#rid3">
          3,4
         </a>
         ]. However, the fall in BP is blunted by hypovolemia-induced activation of the renin-angiotensin system [
         <a href="#rid2">
          2,5
         </a>
         ]. Thus, nonresponders to a thiazide or thiazide-like diuretic may have a diuresis that is equivalent to that in responders, but little or no reduction in BP due to a rise in systemic vascular resistance  (
         <a class="graphic graphic_figure graphicRef76363" href="/z/d/graphic/76363.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. This relationship explains the synergistic response between a diuretic and an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB). These agents block either the generation or the effects of angiotensin II, thereby allowing the full antihypertensive effect of the diuretic to be expressed. (See
         <a class="medical medical_review" href="/z/d/html/3815.html" rel="external">
          "Renin-angiotensin system inhibition in the treatment of hypertension"
         </a>
         .)
        </p>
        <p>
         Long-term maintenance of the decrease in BP is associated with partial reversal of the initial hemodynamic changes: the plasma volume and cardiac output partially rise toward the baseline level, while the systemic vascular resistance falls [
         <a href="#rid3">
          3,4
         </a>
         ]. Despite near-normalization of the plasma volume, it is likely that the plasma volume remains low in relation to the vasodilation-induced increase in the vascular capacity. Two observations are consistent with this hypothesis: (1) the plasma renin activity is persistently elevated; and (2) discontinuation of the diuretic leads to rapid fluid retention before any reversal of the fall in systemic vascular resistance [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Mechanism of vasodilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The secondary vasodilatory response with thiazide diuretics is modest, is most pronounced with longer-acting drugs such as
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         and
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         , and has only a minor role in long-term BP reduction with these agents.
        </p>
        <p>
         The factors responsible for the secondary vasodilation remain unclear. One hypothesis has proposed a central role for a circulating endogenous digitalis-like natriuretic hormone (distinct from atrial natriuretic peptide) that inhibits the cellular Na-K-ATPase pump [
         <a href="#rid7">
          7
         </a>
         ].
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          Chlorthalidone
         </a>
         and
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         could diminish the secretion of this hormone, leading sequentially to a rise in Na-K-ATPase activity, a fall in cell sodium concentration (since more sodium is pumped out of the cell), and increased calcium efflux from the cells. The ensuing decline in the cell calcium concentration then leads to vasodilation and a fall in systemic vascular resistance. This theory, however, has yet to be confirmed.
        </p>
        <p>
         Another possibility is a direct effect upon potassium channels. Modest vasodilation of the forearm in response to
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         can be abolished with the concurrent administration of tetraethylammonium, a calcium-activated potassium channel blocker [
         <a href="#rid8">
          8
         </a>
         ]. Since this is only observed with high doses of hydrochlorothiazide, it is unclear whether a similar effect occurs in patients undergoing chronic low-dose therapy.
        </p>
        <p class="headingAnchor" id="H3353436175">
         <span class="h1">
          EFFICACY AND SAFETY
         </span>
        </p>
        <p class="headingAnchor" id="H299737803">
         <span class="h2">
          Efficacy of low-dose therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with primary hypertension and normal kidney function, thiazide-type and thiazide-like diuretics are typically used at low doses (eg, 12.5 to 25 mg/day of
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         or
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         , or 1.25 mg/day of
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ) to minimize metabolic complications while maintaining the antihypertensive response [
         <a href="#rid9">
          9-15
         </a>
         ].
        </p>
        <p>
         Although higher diuretic doses tend to produce more fluid loss, there may be little or no greater antihypertensive effect because of greater activation of the renin-angiotensin system [
         <a href="#rid5">
          5
         </a>
         ]. More potent thiazide diuretics (ie,
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ), or the use of loop diuretics, may be required in patients with resistant hypertension and/or advanced chronic kidney disease [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3819.html" rel="external">
          "Treatment of resistant hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3871.html" rel="external">
          "Thiazides versus loop diuretics in the treatment of hypertension", section on 'Patients with chronic kidney disease'
         </a>
         .)
        </p>
        <p>
         Used at low doses, the fall in blood pressure (BP) is significantly larger with
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         and
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         as compared with
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         ; in addition, both chlorthalidone and indapamide have been shown to reduce cardiovascular events in randomized trials, whereas there is no evidence that low-dose hydrochlorothiazide alone reduces cardiovascular events:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The benefits of low-dose
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         (12.5 mg/day increased to a maximum of 25 mg/day) were illustrated in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), in which it was compared with
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">
          lisinopril
         </a>
         , and
         <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">
          doxazosin
         </a>
         (the doxazosin arm was prematurely terminated because of an increased risk of heart failure) [
         <a href="#rid17">
          17-19
         </a>
         ]. After almost five years of follow-up, each antihypertensive agent successfully lowered BP (with the goal of less than 140/90 mmHg achieved in approximately 75 percent of patients). Compared with amlodipine and lisinopril, chlorthalidone was associated with the same frequency of the primary end point of cardiovascular death or nonfatal myocardial infarction  (
         <a class="graphic graphic_figure graphicRef82432" href="/z/d/graphic/82432.html" rel="external">
          figure 2
         </a>
         ) but was associated with a significantly lower rate of heart failure  (
         <a class="graphic graphic_figure graphicRef68780" href="/z/d/graphic/68780.html" rel="external">
          figure 3
         </a>
         ) and, compared with lisinopril, stroke  (
         <a class="graphic graphic_figure graphicRef61612" href="/z/d/graphic/61612.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. The interpretation of these findings, however, was somewhat hampered by the fact that the chlorthalidone-based regimen lowered systolic BP more than either the calcium channel blocker-based or the angiotensin-converting enzyme (ACE) inhibitor-based regimen [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          Chlorthalidone
         </a>
         is 1.5 to 2 times as effective as
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         at lowering BP at the same dose given its longer duration of action [
         <a href="#rid20">
          20,21
         </a>
         ]. Thus, although some guidelines recommend 12.5 to 25 mg/day of either drug, one cannot assume that the benefits of chlorthalidone in trials such as ALLHAT would have been replicated with similar doses of hydrochlorothiazide. (See
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          Indapamide
         </a>
         was shown to reduce cardiovascular events in two large trials, including the Hypertension in the Very Elderly Trial (HYVET; in which it was used as initial monotherapy) and the Action in Diabetes and Vascular Disease-PreterAx and DiamicroN Controlled Evaluation (ADVANCE; in which it was given as a fixed-dose combination with
         <a class="drug drug_general" data-topicid="9758" href="/z/d/drug information/9758.html" rel="external">
          perindopril
         </a>
         ) [
         <a href="#rid22">
          22,23
         </a>
         ]. As with
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         , indapamide is a more potent antihypertensive agent than
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         As a result, some experts suggest
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         (12.5 to 25 mg/day) or
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         (1.25 to 2.5 mg/day) as the low-dose diuretic of choice. This issue is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The potential adverse metabolic effects of thiazide and thiazide-like therapy include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dose-dependent metabolic effects – Thiazide diuretics are associated with hypokalemia, hyponatremia, hyperuricemia, hyperglycemia, hyperlipidemia, hypomagnesemia and, occasionally, hypercalcemia. The incidence and magnitude of these side effects are lower with low-dose therapy  (
         <a class="graphic graphic_figure graphicRef69912" href="/z/d/graphic/69912.html" rel="external">
          figure 5
         </a>
         ). (See
         <a class="local">
          'Dose-dependent metabolic effects'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2340.html" rel="external">
          "Diuretics and calcium balance", section on 'Clinical implications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Non-dose-dependent effects – Thiazide diuretics are associated with sexual dysfunction and sleep disturbance. (See
         <a class="local">
          'Non-dose-dependent side effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3901533804">
         <span class="h3">
          Dose-dependent metabolic effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypokalemia, hyponatremia [
         <a href="#rid24">
          24
         </a>
         ], hyperuricemia, elevations in the plasma glucose and cholesterol concentrations, and magnesium depletion can all result from thiazide diuretics [
         <a href="#rid9">
          9
         </a>
         ]. The incidence and magnitude of these side effects are much lower with low-dose therapy (eg, 12.5 to 25 mg/day of
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         or
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         or 1.25 mg/day of
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ), as commonly used in the treatment of primary hypertension  (
         <a class="graphic graphic_figure graphicRef69912" href="/z/d/graphic/69912.html" rel="external">
          figure 5
         </a>
         ) [
         <a href="#rid9">
          9,14,15
         </a>
         ]. By contrast, hypertensive patients who are treated with high doses of a diuretic without a potassium-sparing agent have an increased incidence of sudden cardiac death, presumably as a result of these metabolic disturbances [
         <a href="#rid25">
          25
         </a>
         ]. The incidence of these metabolic perturbations is greater with low doses of chlorthalidone than with low doses of hydrochlorothiazide and indapamide [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="local">
          'Efficacy of low-dose therapy'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">
          "Causes of hypokalemia in adults", section on 'Diuretics'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2288.html" rel="external">
          "Diuretic-induced hyponatremia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2380.html" rel="external">
          "Diuretic-induced hyperuricemia and gout"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3867.html" rel="external">
          "Antihypertensive drugs and lipids"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2340.html" rel="external">
          "Diuretics and calcium balance"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2335.html" rel="external">
          "Effect of diuretics on magnesium handling by the kidney"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In ALLHAT,
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         was associated with a mean reduction in plasma potassium of 0.2 mEq/L, and 8.5 percent of patients required potassium supplements. In addition, chlorthalidone increased the incidence of type 2 diabetes, defined as a fasting blood glucose value of ≥126 mg/dL (7 mmol/L), compared with
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         and
         <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">
          lisinopril
         </a>
         (11.6 versus 9.8 and 8.1 percent, respectively). An increase in risk for new-onset diabetes with thiazide diuretics was also noted in a meta-analysis of trials of antihypertensive agents [
         <a href="#rid26">
          26
         </a>
         ]. The long-term sequelae of new-onset diabetes cannot be appreciated in the usual time frame of trials comparing antihypertensive drugs (which is usually four to five years) [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Some of the adverse effects of thiazide diuretics can be alleviated by combining them with certain other drug classes. The risk of hypokalemia, for example, may be minimized by combining thiazides with ACE inhibitors, angiotensin II receptor blockers (ARBs), mineralocorticoid receptor antagonists (eg,
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         ), or blockers of the epithelial sodium channel (eg,
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         ). These drugs lower BP, which may reduce the required diuretic dose, and prevent renal potassium excretion, which can counteract the hypokalemia associated with diuretics. The same drug classes can also alleviate the impaired glucose tolerance associated with thiazides [
         <a href="#rid28">
          28,29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3815.html" rel="external">
          "Renin-angiotensin system inhibition in the treatment of hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2377.html" rel="external">
          "Causes and evaluation of hyperkalemia in adults", section on 'Reduced urinary potassium excretion'
         </a>
         .)
        </p>
        <p>
         A low-sodium diet, which is recommended for all hypertensive patients, will also reduce the required dose of diuretic and limit the incidence of hypokalemia by reducing sodium delivery to the distal nephron. (See
         <a class="medical medical_review" href="/z/d/html/3877.html" rel="external">
          "Salt intake and hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">
          "Causes of hypokalemia in adults", section on 'Increased urinary losses'
         </a>
         .)
        </p>
        <p>
         Conversely, beta blockers are known to aggravate the perturbations of glucose metabolism associated with thiazides [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1873181298">
         <span class="h3">
          Other dose-dependent side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          Hydrochlorothiazide
         </a>
         enhances DNA damage induced by ultraviolet radiation and therefore may increase the risk of skin cancer [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         In a large, Danish, case-control study, the use of
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         was associated with squamous cell carcinoma of the lip and also with nonmelanoma skin cancers [
         <a href="#rid32">
          32,33
         </a>
         ]. No association was observed with other diuretics or antihypertensive medications. The risk with hydrochlorothiazide was dose dependent and was evident only with large cumulative doses. This implies that prior randomized trials of hydrochlorothiazide, in which patients were typically followed for fewer than five years, would not have detected this relationship.
        </p>
        <p>
         Thiazide-like diuretics (
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         ) are used much less frequently than
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         [
         <a href="#rid34">
          34
         </a>
         ]; fewer data are therefore available, although one study found an association between indapamide and skin cancer [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2250530998">
         <span class="h3">
          Non-dose-dependent side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although low-dose therapy seems to minimize the metabolic complications induced by a thiazide or thiazide-like diuretic, it may not necessarily eliminate other side effects. As an example, as many as 25 percent of men treated with 25 mg/day of
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         develop a decline in sexual function [
         <a href="#rid36">
          36
         </a>
         ]. Sleep disturbances can also occur, particularly if the patient is on a low-sodium diet [
         <a href="#rid36">
          36
         </a>
         ]. How these problems occur is not known.
        </p>
        <p class="headingAnchor" id="H3992806286">
         <span class="h3">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diuretics may induce changes in several laboratory parameters, including reduced serum levels of sodium and potassium and raised serum levels of bicarbonate, creatinine (if the patient becomes hypovolemic), uric acid, and glucose.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2288.html" rel="external">
          "Diuretic-induced hyponatremia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">
          "Causes of hypokalemia in adults", section on 'Increased urinary losses'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2331.html" rel="external">
          "Causes of metabolic alkalosis", section on 'Excessive renal hydrogen loss'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7216.html" rel="external">
          "Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults", section on 'Causes of prerenal disease'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2380.html" rel="external">
          "Diuretic-induced hyperuricemia and gout"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">
          "Pathogenesis of type 2 diabetes mellitus", section on 'Drug-induced hyperglycemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Strong data regarding how and when to monitor for these abnormalities are lacking. We usually measure these parameters once within the first one to two weeks of initiating treatment and again after 6 to 12 months. We monitor more frequently if the dose is intensified or if the patient becomes symptomatic and the diuretic is thought to be at least in part responsible for the symptoms (for example, if dizziness or cardiac rhythm abnormalities are reported).
        </p>
        <p>
         In addition, we instruct patients to temporarily halt their diuretics if they develop an intermittent disorder that can contribute to hypovolemia, such as diarrhea, vomiting or decreased food intake, or fever. Once the intermittent illness resolves, the diuretic can be resumed.
        </p>
        <p class="headingAnchor" id="H2049338128">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109601.html" rel="external">
          "Society guideline links: Hypertension in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20103260">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mechanisms responsible for the decline in blood pressure (BP) with thiazide diuretics are incompletely understood. The BP response appears to require initial volume loss since it is not seen in patients who are resistant to the diuretic or who are ingesting a high-salt diet. The BP in responders begins to fall within the first week, but a slow decline can continue for as long as 12 weeks. Longer-acting diuretics are more effective than short-acting loop diuretics in patients with mild to moderate primary hypertension because they maintain the decline in intravascular volume. The fall in BP is blunted by hypovolemia-induced activation of the renin-angiotensin system. Long-term maintenance of the decrease in BP is associated with partial reversal of the initial hemodynamic changes: the plasma volume and cardiac output partially rise toward the baseline level, while the systemic vascular resistance falls (secondary vasodilation). (See
         <a class="local">
          'Antihypertensive mechanism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with primary hypertension and normal kidney function, thiazide-type and thiazide-like diuretics are typically used at low doses (eg, 12.5 to 25 mg/day of
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         or
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         , or 1.25 mg/day of
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ) to minimize metabolic complications while maintaining the antihypertensive response. Although higher diuretic doses tend to produce more fluid loss, there may be little or no greater antihypertensive effect because of greater activation of the renin-angiotensin system. (See
         <a class="local">
          'Efficacy of low-dose therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Used at low doses, the fall in BP is significantly larger with
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         and
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         as compared with
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         ; in addition, both chlorthalidone and indapamide have been shown to reduce cardiovascular events in randomized trials, whereas there is no evidence that low-dose hydrochlorothiazide alone reduces cardiovascular events. As a result, some experts suggest chlorthalidone (12.5 to 25 mg/day) or indapamide (1.25 to 2.5 mg/day) as the low-dose diuretic of choice. (See
         <a class="local">
          'Efficacy of low-dose therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The potential adverse metabolic and other effects of thiazide therapy include (see
         <a class="local">
          'Side effects'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dose-dependent metabolic effects – Thiazide diuretics are associated with hypokalemia, hyponatremia, hyperuricemia, hyperglycemia, hyperlipidemia, and hypomagnesemia. The incidence and magnitude of these side effects are lower with low-dose therapy  (
         <a class="graphic graphic_figure graphicRef69912" href="/z/d/graphic/69912.html" rel="external">
          figure 5
         </a>
         ). (See
         <a class="local">
          'Dose-dependent metabolic effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The risk of hypokalemia, for example, may be minimized by combining thiazides with angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), mineralocorticoid receptor antagonists (eg,
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         ), or blockers of the epithelial sodium channel (eg,
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         ). A low-sodium diet will reduce the required dose of the diuretic and also limit the incidence of hypokalemia by reducing sodium delivery to the distal nephron. Conversely, beta blockers are known to aggravate the perturbations of glucose metabolism associated with thiazides.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other dose-dependent effects – Large cumulative doses of thiazide diuretics may increase the risk of squamous cell carcinoma of the lip and other nonmelanoma skin cancers.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Non-dose-dependent effects – Thiazide diuretics are associated with sexual dysfunction and sleep disturbance. (See
         <a class="local">
          'Non-dose-dependent side effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We usually measure the serum sodium, potassium, and creatinine once within the first one to two weeks after initiating treatment and again after 6 to 12 months. We monitor more frequently if the dose is intensified or if the patient becomes symptomatic and the diuretic is thought to be at least in part responsible for the symptoms.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3596813061">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Norman Kaplan, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kaplan NM. Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare. Hypertension 2011; 58:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freis ED, Reda DJ, Materson BJ. Volume (weight) loss and blood pressure response following thiazide diuretics. Hypertension 1988; 12:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Brummelen P, Man in 't Veld AJ, Schalekamp MA. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther 1980; 27:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah S, Khatri I, Freis ED. Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 1978; 95:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaughan ED Jr, Carey RM, Peach MJ, et al. The renin response to diuretic therapyl A limitation of antihypertensive potential. Circ Res 1978; 42:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarazi RC, Dustan HP, Frohlich ED. Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity. Circulation 1970; 41:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blaustein MP. Endogenous ouabain: role in the pathogenesis of hypertension. Kidney Int 1996; 49:1748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pickkers P, Hughes AD, Russel FG, et al. Thiazide-induced vasodilation in humans is mediated by potassium channel activation. Hypertension 1998; 32:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Materson BJ, Cushman WC, Goldstein G, et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study. Hypertension 1990; 15:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289:2534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harper R, Ennis CN, Sheridan B, et al. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ 1994; 309:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freis ED, Thomas JR, Fisher SG, et al. Effects of reduction in drugs or dosage after long-term control of systemic hypertension. Am J Cardiol 1989; 63:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998; 158:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014; :CD003824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med 2021; 385:2507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283:1967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009; 361:2153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung AA, Wright A, Pazo V, et al. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med 2011; 124:1064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330:1852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilgers KF, Mann JF. The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations? Nephrol Dial Transplant 2008; 23:3389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown MJ, Williams B, Morant SV, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 2016; 4:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sowers JR, Raij L, Jialal I, et al. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens 2010; 28:1761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunisada M, Masaki T, Ono R, et al. Hydrochlorothiazide enhances UVA-induced DNA damage. Photochem Photobiol 2013; 89:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pottegård A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedersen SA, Gaist D, Schmidt SAJ, et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78:673.
          </a>
         </li>
         <li class="breakAll">
          https://clincalc.com/DrugStats/Top300Drugs.aspx (Accessed on January 24, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen AØ, Thomsen HF, Engebjerg MC, et al. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer 2008; 99:1522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med 1991; 114:613.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3860 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22025371" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3049338" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Volume (weight) loss and blood pressure response following thiazide diuretics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6987024" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/637001" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mechanism of antihypertensive effect of thiazide diuretics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/624143" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The renin response to diuretic therapyl A limitation of antihypertensive potential.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5437415" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8743490" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Endogenous ouabain: role in the pathogenesis of hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9856976" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Thiazide-induced vasodilation in humans is mediated by potassium channel activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2344503" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2318517" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12759325" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7818648" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2646896" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effects of reduction in drugs or dosage after long-term control of systemic hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9554680" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24869750" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34739197" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12479763" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19433694" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10789664" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16432050" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19940300" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Use of diuretics in patients with hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378519" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Treatment of hypertension in patients 80 years of age or older.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17765963" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22017784" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Risk of thiazide-induced hyponatremia in patients with hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8196728" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Diuretic therapy for hypertension and the risk of primary cardiac arrest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17240286" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18687734" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26489809" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20498618" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16331092" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : New-onset diabetes and antihypertensive drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23331297" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hydrochlorothiazide enhances UVA-induced DNA damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28480532" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Hydrochlorothiazide use is strongly associated with risk of lip cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29217346" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29217346" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18813314" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2003706" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effect of antihypertensives on sexual function and quality of life: the TAIM Study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
